Clarkston Capital Partners LLC Has $63.28 Million Holdings in Medpace Holdings, Inc. $MEDP

Clarkston Capital Partners LLC lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 123,064 shares of the company’s stock after selling 6,195 shares during the period. Medpace accounts for 1.4% of Clarkston Capital Partners LLC’s portfolio, making the stock its 26th largest holding. Clarkston Capital Partners LLC owned 0.44% of Medpace worth $63,275,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. NewEdge Advisors LLC increased its position in Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after buying an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after buying an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Medpace in the second quarter worth $296,000. Finally, Aviva PLC grew its stake in shares of Medpace by 58.5% in the second quarter. Aviva PLC now owns 2,883 shares of the company’s stock worth $905,000 after acquiring an additional 1,064 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Trading Up 0.3%

NASDAQ:MEDP opened at $470.59 on Monday. The stock has a market capitalization of $13.36 billion, a P/E ratio of 30.76, a price-to-earnings-growth ratio of 2.26 and a beta of 1.44. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The firm has a 50 day moving average of $533.94 and a 200-day moving average of $539.47.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same period in the previous year, the business posted $3.67 earnings per share. The firm’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Mizuho set a $582.00 price objective on shares of Medpace in a report on Wednesday, February 11th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and reduced their target price for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. BMO Capital Markets reissued a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Finally, Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a report on Friday, February 13th. Five analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.